137 related articles for article (PubMed ID: 3300097)
1. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
Klebingat KJ; Panzig E; Lorenz G; Steinhauser I; Fiedler R
Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
[TBL] [Abstract][Full Text] [Related]
2. [Liver damage in hormone therapy of prostate cancer].
Zade W; Schott H
Z Urol Nephrol; 1987 Mar; 80(3):177-9. PubMed ID: 3604474
[TBL] [Abstract][Full Text] [Related]
3. [Clinical value of ethinyl estradiol sulfonate (Turisteron)--long-term results of a randomized compound study].
Böhm WD; Gorski J; Geissler W; Illig HD; Koch R
Z Urol Nephrol; 1987 Mar; 80(3):159-64. PubMed ID: 2440199
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition of the free, biologically active testosterone level by Turisteron in patients with prostate cancer].
Stahl F; Schnorr D; Rohde W; Dörner G
Z Urol Nephrol; 1987 Mar; 80(3):135-8. PubMed ID: 3604472
[TBL] [Abstract][Full Text] [Related]
5. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
Benson RC; Cummings K
Prog Clin Biol Res; 1989; 303():177-86. PubMed ID: 2674984
[No Abstract] [Full Text] [Related]
6. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
Hauchecorne J
Prog Clin Biol Res; 1987; 243B():229-34. PubMed ID: 3309983
[No Abstract] [Full Text] [Related]
7. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
Nickel CJ; Morales A
Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
[TBL] [Abstract][Full Text] [Related]
8. [Clinical experience using Turisteron in the treatment of prostatic cancer].
Sladczyk E
Z Urol Nephrol; 1987 Mar; 80(3):181-3. PubMed ID: 3604475
[TBL] [Abstract][Full Text] [Related]
9. [Initial results of a phase IV multicenter clinical trial of Turisteron in the treatment of prostate cancer].
Guddat HM; Schnorr D; Zemke F
Z Urol Nephrol; 1987 Mar; 80(3):165-70. PubMed ID: 3300098
[TBL] [Abstract][Full Text] [Related]
10. [Conservative therapy of prostate cancer using Turisteron].
Schnorr D; Dörner G; Stahl F; Rohde W; Guddat HM
Z Urol Nephrol; 1987 Mar; 80(3):149-57. PubMed ID: 3111122
[TBL] [Abstract][Full Text] [Related]
11. The EORTC Phase III trials in prostatic cancer.
Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
[No Abstract] [Full Text] [Related]
12. Randomised, double-blind study of estramustine phosphate and leuprolide acetate.
De la Grange AB
Prog Clin Biol Res; 1987; 243B():227-8. PubMed ID: 3116555
[No Abstract] [Full Text] [Related]
13. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
Kalland T; Haukaas S
Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
[TBL] [Abstract][Full Text] [Related]
14. [Plasma changes caused by estrogens in the vascular risk of prostatic carcinoma over a 3-year period].
Daponte DP; Stevens I; Robinson MR
Actas Urol Esp; 1986; 10(6):437-40. PubMed ID: 3825644
[No Abstract] [Full Text] [Related]
15. Estramustine for prostate cancer.
Med Lett Drugs Ther; 1982 Aug; 24(615):74. PubMed ID: 7099111
[No Abstract] [Full Text] [Related]
16. [Serum testosterone and acid phosphatase levels in patients with prostatic cancer treated with Estracyt].
Németh A; Morvay J; Vécsei B
Orv Hetil; 1981 Apr; 122(17):1017-20. PubMed ID: 7022313
[No Abstract] [Full Text] [Related]
17. [Treatment of hormone-resistant prostate cancer with estramustine phosphate (Estracyt)].
Stridsklev IC; Fosså SD; Kaalhus O
Tidsskr Nor Laegeforen; 1984 Oct; 104(28):1977-80. PubMed ID: 6388019
[No Abstract] [Full Text] [Related]
18. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
Benson RC; Gill GM; Cummings KB
Semin Oncol; 1983 Sep; 10(3 Suppl 3):43-5. PubMed ID: 6364366
[No Abstract] [Full Text] [Related]
19. [Experiences in the treatment of advanced prostatic cancer using Turisteron with special reference to cardiovascular complications].
Drawz B; Hoffmann L; Drawz G; Russbüldt R
Z Urol Nephrol; 1987 Mar; 80(3):171-5. PubMed ID: 3604473
[TBL] [Abstract][Full Text] [Related]
20. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
[No Abstract] [Full Text] [Related]
[Next] [New Search]
